drugset / Trial / NCT00963924

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

NCT00963924

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. We will test the hypotheses that D-cycloserine will significantly improve cognitive performance, negative symptoms, and measures of functioning compared to placebo when combined with eight weeks of cognitive remediation. We expect that these effects will persist when assessed at six-month follow up.

Timeline

Start
2009-08
Primary completion
2011-05
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cycloserine Small molecule 50 mg Oral

Indications